Swiss Life Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Swiss Life Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$220K	Buy	+5,871	New	+$218K	﹤0.01%	1474

Other funds holding CRNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Swiss Life Asset Management's CRNX Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 5,871 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #1474 among its holdings.

149 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Swiss Life Asset Management held 5,871 shares of Crinetics Pharmaceuticals worth $220K as of Q2 2026.
Crinetics Pharmaceuticals was a new Swiss Life Asset Management position in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1474 holding.
149 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.